tracked. This update does not introduce a new thesis; it gives the existing one more structure. FY2025 revenue rose to USD 124,157, gross profit turned positive at USD 102,911, gross margin reached 82.9%, and the filed 10-K shows that 99.4% of FY2025 revenue came from AI Nose-related programs. That matters because the near-term commercial story is now being carried much more clearly by industrial smelltech, not by broad platform optionality alone.
The more important change is on execution visibility. Management now points to around 200 front-end wafer-fab systems targeted for technical validation, around 1,400 systems under the previously disclosed three-year USD 2.1 million ASE framework, a disclosed ~USD 350k deposit, and a stated Q2 2026 completion target for that rollout phase. The 10-K also adds a contracted minimum commitment of 600 AI Nose units with a semiconductor engineering and systems-integration partner, while ~USD 2.82 million of financing from an ASE group company strengthens liquidity.
The correct investor read remains disciplined: Ainos is moving from proof-of-concept toward early commercial execution, but broader scale-up still depends on validation results and contractual conversion. What has improved is not certainty of full rollout, but the number of visible checkpoints the market can now track.
Access the Update - 01 April 2026
The post Ainos Update - FY2025 and the 10-K Add Structure to 2026 AI Nose Execution appeared first on VASRO GmbH.
